Roth MKM initiated coverage of GT Biopharma (GTBP) with a Buy rating and $11 price target Clinical-stage GT is developing unique precision therapeutic agents using camelid-derived nanobodies, the analyst tells investors in a research note. The firm says the drugs are designed to treat various cancers and autoimmune disorders, and the versatility of these nanobodies enables them to be engineered for optimal therapeutic effects, offering potential benefits such as reduced side effects and more convenient routes of delivery.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GTBP: